首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 基因疗法

基因治疗市场规模、份额和成长分析（按基因类型、治疗方法、载体类型、递送方法、给药途径、应用和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1899716

基因治疗市场规模、份额和成长分析（按基因类型、治疗方法、载体类型、递送方法、给药途径、应用和地区划分）－2026-2033年产业预测

Gene Therapy Market Size, Share, and Growth Analysis, By Gene Type (Antigen, Cytokine), By Therapy type, By Vector type, By Delivery Method, By Route of Administration, By Application, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 194 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球基因治疗市场规模预计在 2024 年达到 90 亿美元，从 2025 年的 109.3 亿美元成长到 2033 年的 515.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 21.4%。

在全球基因治疗市场持续强劲成长的推动下，科学的重大进步和遗传性疾病发生率的上升趋势日益显着。血友病和囊肿纤维化等罕见疾病和慢性病的盛行率不断攀升，推动了标靶基因治疗方法的发展。 CRISPR-Cas9 和腺结合病毒载体等创新技术提高了基因转移方法的精准性和安全性。关键治疗方法的监管核准进一步刺激了投资和研究。然而，挑战依然存在，包括治疗费用高昂导致的可及性受限、病毒载体复杂的生产流程、免疫反应方面的安全隐患以及监管障碍，尤其是在新兴市场。儘管有这些限制，但正在进行的临床试验、技术整合以及不断增长的资金筹措表明，该市场前景光明。

全球基因治疗市场按基因类型、治疗方法类型、载体类型、递送方法、给药途径、应用、最终用户和地区进行细分。依基因类型划分，市场分为抗原、细胞激素、抑癌基因、自杀基因、缺陷基因、受体和其他基因。依治疗方法类型划分，市场分为基因静默疗法、细胞替代疗法、基因增强疗法和其他治疗方法。依载体类型划分，市场分为病毒载体和非病毒载体。依递送方法划分，市场分为体外和体内递送。

全球基因治疗市场驱动因素

全球基因治疗领域正蓬勃发展，基因编辑技术的快速发展，尤其是CRISPR-Cas9等工具的出现，对其产生了显着影响。这些创新技术提高了基因修饰的精准性、有效性和安全性，简化了临床开发流程，并为患者拓展了治疗选择。此外，载体疗法的发展以及递送机制的改进，也进一步推动了该领域的成长。随着这些技术的不断进步，它们正为治疗格局带来变革性的影响，使研究人员和医疗服务提供者能够探索治疗遗传疾病的新途径，并改善患者的治疗效果。

限制全球基因治疗市场的因素

全球基因治疗市场成长面临许多限制因素，包括长期安全性、脱靶效应和伦理挑战。这些担忧可能导致公众和监管机构的质疑，从而延缓创新治疗方法的推出。此外，由于相关人员需要解决围绕基因工程的复杂问题，这种不确定性可能会抑制投资并阻碍整体市场发展。这些因素共同构成了基因治疗发展和普及的重大挑战，最终影响医疗保健领域创新治疗方案的潜力。

全球基因治疗市场趋势

全球基因治疗市场的一个显着趋势是，在基因组学和生物技术进步的推动下，精准医疗日益受到重视。这种转变使得针对个体基因谱量身订做标靶治疗成为可能，从而提高了治疗的有效性和安全性。此外，遗传性疾病和慢性病的盛行率上升也推动了对基因治疗的投资，因为相关人员认识到基因治疗在满足未被满足的医疗需求方面的潜力。製药公司与研究机构之间的合作也在增加，这促进了创新，加速了基因治疗的商业化进程，从而扩大了基因治疗的可及性，并改善了全球患者的治疗效果。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Krystal Biotech（United States）
CRISPR Therapeutics（Switzerland）
Beam Therapeutics（United States）
Intellia Therapeutics（United States）
Korro Bio（United States）
Neurogene（United States）
Sangamo Therapeutics（United States）
MeiraGTx（United States）
Verve Therapeutics（United States）
Prime Medicine（United States）
Taysha Gene Therapies（United States）
enGene（Canada）
Voyager Therapeutics（United States）
Poseida Therapeutics（United States）
uniQure（Netherlands）
Editas Medicine（United States）
Benitec Biopharma（United States）
Cellectis SA（France）
Adverum Biotechnologies（United States）
Generation Bio（United States）

结论与建议

简介目录

Product Code: SQMIG35H2218

Global Gene Therapy Market size was valued at USD 9.00 Billion in 2024 and is poised to grow from USD 10.93 Billion in 2025 to USD 51.55 Billion by 2033, growing at a CAGR of 21.4% during the forecast period (2026-2033).

The global gene therapy market is witnessing robust expansion driven by significant scientific advancements and the rising prevalence of genetic disorders. Increasing rates of rare and chronic conditions, such as hemophilia and cystic fibrosis, are catalyzing the development of targeted gene-based therapies. Innovations like CRISPR-Cas9 and adeno-associated virus vectors have improved the precision and safety of gene delivery methods. Regulatory endorsements of prominent therapies have spurred further investment and research. However, challenges remain, including high treatment costs that limit accessibility, complex production of viral vectors, safety concerns regarding immune responses, and regulatory hurdles, particularly in emerging markets. Despite these constraints, ongoing clinical trials and technological integrations, alongside increased funding, hint at a promising trajectory for the market's future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gene Therapy Market Segments Analysis

The global gene therapy market is segmented by Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user and region. Based on Gene Type, the market is segmented into Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Receptors and Others. Based on Therapy type, the market is segmented into Gene silencing therapy, Cell replacement therapy, Gene augmentation therapy and Other therapies. Based on Vector type, the market is segmented into Viral vector and Non-Viral Vector. Based on Delivery Method, the market is segmented into Ex-Vivo and In-Vivo.

Driver of the Global Gene Therapy Market

The expanding global gene therapy sector is significantly influenced by swift progress in gene editing techniques, particularly tools like CRISPR-Cas9. These innovative technologies enhance the precision, effectiveness, and safety of genetic modifications, thereby streamlining the clinical development process and broadening treatment options for patients. Furthermore, the development of vector-based methods coupled with improved delivery mechanisms is further driving growth in this field. As these advancements continue to evolve, they pave the way for a transformative impact on the therapeutic landscape, enabling researchers and healthcare providers to explore new possibilities in treating genetic disorders and enhancing patient outcomes.

Restraints in the Global Gene Therapy Market

The growth of the global gene therapy market faces various constraints, including concerns related to long-term safety, off-target effects, and ethical implications. These apprehensions may lead to skepticism among the public and regulatory bodies, potentially stalling the adoption of innovative therapies. Additionally, such uncertainties could deter investment and inhibit overall market development as stakeholders navigate the complexities surrounding genetic engineering. The combination of these factors can create significant challenges for the advancement and acceptance of gene therapies, ultimately impacting their potential to revolutionize treatment options in the healthcare sector.

Market Trends of the Global Gene Therapy Market

A significant trend in the global gene therapy market is the increasing focus on precision medicine, driven by advancements in genomics and biotechnology. This shift is enabling the development of targeted therapies that cater to individual genetic profiles, enhancing treatment efficacy and safety. Additionally, the rising prevalence of genetic disorders and chronic diseases is propelling investment in gene therapies, as stakeholders recognize their potential to address unmet medical needs. Collaborations between pharmaceutical companies and research institutions are also on the rise, facilitating innovation and accelerating the commercialization of gene therapies, thereby expanding access and improving patient outcomes globally.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Gene Therapy Market Size by Gene Type & CAGR (2026-2033)

Market Overview
Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Receptors
Others

Global Gene Therapy Market Size by Therapy type & CAGR (2026-2033)

Market Overview
Gene silencing therapy
Cell replacement therapy
Gene augmentation therapy
Other therapies

Global Gene Therapy Market Size by Vector type & CAGR (2026-2033)

Market Overview
Viral vector
- Retroviral vectors
- AAV Vectors
- Others
Non-Viral Vector
- Oligonucleotide Vectors
- Others

Global Gene Therapy Market Size by Delivery Method & CAGR (2026-2033)

Market Overview
Ex-Vivo
In-Vivo

Global Gene Therapy Market Size by Route Of Administration & CAGR (2026-2033)

Market Overview
Intravenous Route
Subcutaneous Route
Others

Global Gene Therapy Market Size by Application & CAGR (2026-2033)

Market Overview
Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Disease
Other Diseases

Global Gene Therapy Market Size by End-user & CAGR (2026-2033)

Market Overview
Cancer Institutes
Hospitals
Research institutes
Others

Global Gene Therapy Market Size & CAGR (2026-2033)

North America (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- US
- Canada
Europe (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- Brazil
- Rest of Latin America
Middle East & Africa (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Krystal Biotech (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beam Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intellia Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Korro Bio (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurogene (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MeiraGTx (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Verve Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Prime Medicine (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Taysha Gene Therapies (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
enGene (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Voyager Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Poseida Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
uniQure (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Benitec Biopharma (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellectis S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Generation Bio (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments